Pharmacogenomic (PGx) Consensus Recommendations

These consensus recommendations endorsed by 12 organizations identify key steps to improve equitable pharmacogenomic (PGx) discovery and  implementation in oncology. PGx testing is a form of personalized medicine that  helps us understand how inherited genomic variation is associated with the clinical effectiveness or toxicity of drugs. Despite its power to improve patient outcomes, PGx testing has not been fully implemented, and where it has been implemented it is often done so inequitably. 

For additional background, including evidence supporting these recommendations, see our 2024 paper Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology (and ACS CAN's press release).